Epidemiology and Healthcare Burden Attributable to Laboratory-Confirmed RSV Cases Among Children Under Five Years Old in Saudi Arabia
An overview of the latest Saudi evidence presented at ESPID 2026.
This website is intended exclusively for healthcare professionals residing and/or working in the UAE.

An overview of the latest Saudi evidence presented at ESPID 2026.
This video provides a clear overview of graft-versus-host disease, exploring its key classifications and the underlying immunological mechanisms that drive disease development and progression. It aims to support understanding of GvHD pathophysiology to inform diagnosis, management, and therapeutic decision-making.
Summary of Kuwait’s updated RSV prevention policy
Drawing on data NirseGAL, this page provides healthcare professionals with evidence-based insights into nirsevimab's sustained protective impact across two consecutive RSV seasons
Recognizing the key cytokines driving type 2 inflammation and understanding their profound impact on patients’ asthma burden is crucial.1-3

What’s New in the GOLD 2026 Report

Progression Independent of Relapse Activity (PIRA) represents the gradual, sustained worsening of disability that occurs even without relapses. In this video, Dr. Barry Singer explains how PIRA is defined, why it affects many patients across the MS spectrum, and how clinicians can better detect subtle changes that reflect true long-term progression.

Kaplan–Meier curves play a key role in visualizing how clinical events—such as confirmed disability progression—evolve over time in MS studies. In this video, Dr. Barry Singer provides a clear, simplified walkthrough of how these curves are constructed, how patient data contributes to each step, and what curve separation really tells us about treatment impact. This resource offers an accessible foundation for anyone looking to better understand KM interpretation in MS research.